MedTrace Logo

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

NCT00504699 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-03-29

No results posted yet for this study

Summary

Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase their estrogen levels in blood.this may stimulate their cancer and increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole), this may increase the safety of stimulation. In this study we compared ovarian stimulation in breast cancer patients using letrozole with those who did not undergo stimulation and showed that there is no increase risk for recurrence after a median follow up of 2 years

Conditions

Interventions

PROCEDURE

Ovarian stimulation in vitro fertilization cryopreservation

Letrozole 5 mg/day during ovarian stimulation

Sponsors & Collaborators

  • New York Medical College

    lead OTHER

Principal Investigators

  • Kutluk H Oktay, MD, FACOG · IFP

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2018-03-01
Completion
2018-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504699 on ClinicalTrials.gov